MicroRNA sponges: competitive inhibitors of small RNAs in mammalian cells

By Margaret S. Ebert, J. Neilson, Phillip A. Sharp. Nature Methods, 2007

2,167 citations recorded by the source corpus.

Subfields: Cancer Research, Molecular Biology

View Paper: https://www.semanticscholar.org/paper/e7a457c6c8f1e7265b1a95e1e2c8265cb7fe417f

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cancer Research

1. David P. Bartel
2. Phillip A. Sharp
3. John S. Mattick
4. Margaret S. Ebert
5. Igor Ulitsky
6. Yvonne Tay
7. Marcel E. Dinger
8. Danish H Sayed

In Molecular Biology

1. David P. Bartel
2. John S. Mattick
3. Phillip A. Sharp
4. Margaret S. Ebert
5. Igor Ulitsky
6. Yvonne Tay
7. Marcel E. Dinger
8. Ling-Ling Chen

Citations in the corpus

• MicroRNAs and their targets: recognition, regulation and an emerging reciprocal relationship (2012, background): “Even before the vast potential of natural miRNA target decoys was realized, transcripts that could sequester specific miRNAs were developed as experimental tools in plant and animal cell”
• Reversion of advanced Ebola virus disease in nonhuman primates with ZMapp™ (2014, background): “Highly expressed site-containing RNAs, either found naturally or delivered as research reagents, can act as ‘‘sponges’’ to titrate miRNAs away from other normal targets (Ebert et al., 2007; Franco-Zorrilla et al., 2007; Mukherji et al., 2011; Hansen et al., 2013; Memczak et al., 2013).”
• MicroRNAs: New Biomarkers for Diagnosis, Prognosis, Therapy Prediction and Therapeutic Tools for Breast Cancer (2015, methodology): “In recent years, a method has been described to inhibit miRNA function using synthetic mRNAs containing multiple binding sites for a specific miRNA, called miRNA sponges [232, 233].”
• Roles for microRNAs in conferring robustness to biological processes. (2012, positive): “However, what is lacking from these reports is a quantitative analysis of the molecules involved: how many molecules per cell of ceRNAs are competing for how many molecules of the miRNAs, against how many molecules of other target mRNAs? For reference, artificial miRNA target decoys or sponges that ”
• MicroRNA dysregulation in cancer: diagnostics, monitoring and therapeutics. A comprehensive review (2012, neutral): “Ebert et al (Ebert et al, 2007) developed miRNA inhibitory transgenes, called ‘miRNA sponges’, expressing an mRNA containing multiple tandem binding sites for an endogenous miRNA and thus able to stably interact with the corresponding miRNA and prevent the association with its endogenous targets.”
• A ceRNA hypothesis: the Rosetta stone of a hidden RNA language? (2011, background): “Approximately three years before the identification of these endogenous Cell 1 decoys, numerous studies found that exogenously expressed ‘‘microRNA sponges’’ were able to inhibit microRNA function specifically and effectively (Ebert et al., 2007; Brown et al., 2007; Gentner et al., 2009).”
• Circular RNAs are abundant, conserved, and associated with ALU repeats. (2013, background): “…mammals suggest that expression of some ncRNAs can perturb miRNA function by “target mimicry,” where ncRNAs such as those produced by pseudogenes sequester miRNAs to prevent translational repression of target coding RNA species (Ebert et al. 2007; Franco-Zorrilla et al. 2007; Poliseno et al. 2010).”
• MicroRNAs in development and disease. (2011, background): “Conversely, one can envision the delivery of viral vectors that express specific antisense miRNA-targeting constructs, such as the “eraser” (497, 534) or the “sponge” (152) for reducing the levels of upregulated miRNA in diseased organs, which awaits testing.”
• A Pleiotropically Acting microRNA, miR-31, Inhibits Breast Cancer Metastasis (2009, neutral): “The latter are expression constructs that carry miRNA recognition motifs in their 30 UTR that bind and thus titer miRNAs (Ebert et al., 2007).”
• lincRNAs: Genomics, Evolution, and Mechanisms (2013, positive): “Another proposed function of mammalian lincRNAs is to pair to microRNAs and titrate them away from their mRNA targets, as can be done using artificial ‘‘sponge’’ RNAs (Ebert et al., 2007) and as observed for select plant and viral RNAs (Franco-Zorrilla et al.”
• Targeting MicroRNAs in Cancer: Rationale, Strategies and Challenges (2010, neutral): “Ebert and colleagues recently reported the use of miRNA sponges in mammalian cell”
• MicroRNA miR-326 regulates TH-17 differentiation and is associated with the pathogenesis of multiple sclerosis (2009, background): “The term 'sponge' refers to a miR-326-specific decoy target known to suppress endogenous miR-326 activity without affecting its transcript amount”